Registry update — unassessed
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 1, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- This is a phase II dose-finding study with no efficacy results reported, so no claims can be made about whether fisetin actually reduces sepsis progression or organ failure
- The adaptive allocation design and focus on identifying an efficacious dose means this trial is not powered to definitively establish clinical benefit—that is reserved for a future phase III trial
- Sample size and effect sizes are not reported, preventing assessment of statistical power or the magnitude of any observed differences
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Older patients with sepsis
- Primary outcome
- Composite cardiovascular, respiratory, and renal sequential organ failure assessment (SOFA) score reduction at 1 week
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Minnesota
- Published
- Sep 1, 2026
Sources
Primary source
- University of Minnesota ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 2. This is not a claim of full-text review.
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
A multicenter, randomized, adaptive allocation clinical trial to identify the most efficacious dose of the senolytic fisetin to reduce the composite cardiovascular, respiratory, and renal sequential organ failure assessment score at 1 week
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.